Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 25, 2025World Journal of Clinical OncologyOpen Access

Are we overestimating success of salvage hepatectomy in unresectable hepatocellular carcinoma?

View Full Paper
Ask AI
Bookmark
Share

Authors

BMBabu Lal MeenaDSDeepti Sharma

Discussion

Loading...

Member takes

Overview

This study assesses salvage hepatectomy outcomes after downstaging in hepatocellular carcinoma patients, suggesting careful patient selection is crucial.

Key Points

  • Salvage hepatectomy may not yield the success rates previously estimated in unresectable hepatocellular carcinoma.
  • The study highlights that various downstaging modalities, such as trans arterial chemoembolization, are used in treatment plans.
  • Proper patient selection is emphasized as a critical factor to reduce risks of salvage-related liver failure.
  • Downstaging procedures, including tyrosine kinase inhibitors and anti-PD-1 antibodies, play an essential role in managing advanced liver cancer.

Cite This Study

Meena et al. (2025) studied this question.

synapsesocial.com/papers/68d5bd72dc445aa9033b0cbdhttps://doi.org/10.5306/wjco.v16.i9.111537
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Surgery for postoperative intrahepatic recurrence after curative resection for hepatocellular carcinoma: Repeat hepatectomy versus salvage liver transplantation2025
  2. 2Transarterial chemoembolization for advanced hepatocellular carcinoma after failure of first-line systemic treatment: a single-center case series2025 · 3 citations
  3. 3The role of radiological interventions in hepatocellular carcinoma before liver transplantation: a surgical perspective2025
  4. 4Impact of Surgical Resection on Hepatocellular Carcinoma Following Systemic Drug Therapy: A Multicenter Retrospective Observational Study2025
  5. 5Short-term results of salvage surgery after immune and target therapies in non-small cell lung cancer2025